Impact of Yaq-001, a non-absorbable, engineered carbon bead of controlled porosity in rodent models of cirrhosis and acute on chronic liver failure

Jinxia Liu, Jane Macnaughtan, Yi Jin, Frederick Clasen, Abeba Habtesion, Alexandra Phillips, Francesco De Chiara, Ganesh Ingavle, Paul Cordero-Sanchez, Junpei Soeda, Jude A. Oben, Jia Li, Haifeng Wu, Lindsey Edwards, I. Jane Cox, Susan Sandeman, Nathan Davies, Rajeshwar P. Mookerjee, Gautam Mehta, Saeed Shoaie, Julian R. Marchesi, Fausto Andreola, Rajiv JalanbioRxiv 2023 · DOI

Abstract

Translocation of gut bacterial lipopolysaccharide (LPS) is a primary driver of complications in cirrhosis. Current therapeutic strategies are largely limited to antibiotics, which carry the risk of antimicrobial resistance. This study evaluates Yaq-001, a non-absorbable, engineered carbon bead with tailored porosity, as a novel treatment for cirrhosis and acute-on-chronic liver failure (ACLF). Using in vitro assays and two rodent models—bile duct ligation (BDL) for cirrhosis and BDL-LPS for ACLF—researchers assessed organ function, systemic inflammation, and multi-omic signatures. Results demonstrated that Yaq-001 rapidly adsorbs endotoxins and bile acids without antibiotic effects. In vivo, treatment significantly improved liver injury markers, portal pressure, renal function, and survival rates. These findings provide a strong preclinical rationale for Yaq-001 as a gut-restricted therapy to prevent complications in patients with chronic liver disease.

Introduction

In advanced cirrhosis, the intestinal barrier becomes increasingly permeable, or "leaky." This allows gut-derived toxins, particularly bacterial lipopolysaccharides (LPS or endotoxins), to translocate into the portal and systemic circulation. This translocation triggers a cascade of systemic inflammation that can precipitate Acute-on-Chronic Liver Failure (ACLF), a syndrome characterized by rapid multi-organ failure (kidneys, brain, and liver) and high mortality.

Historically, clinicians have relied on antibiotics like rifaximin to manage gut bacterial load. However, long-term antibiotic use is a "double-edged sword," as it disrupts microbiome diversity and promotes the emergence of multi-drug resistant organisms. There is an urgent clinical need for a "gut-restricted" therapy that can neutralize toxins and metabolites without exerting the selective pressure of an antibiotic. Yaq-001 was developed to fill this gap as a non-absorbable "molecular sponge."

Mechanism of Action: The Engineered Carbon Bead

Yaq-001 is a synthetic activated carbon bead characterized by bimodal porosity, designed to target specific classes of toxins:

  • Micropores (<2nm): Optimized to capture smaller molecules such as ammonia and bile acids.
  • Meso-macropores (30-200nm): Specifically tailored to adsorb larger biologically active toxins, including LPS and inflammatory cytokines.

Unlike traditional charcoal or antibiotics, Yaq-001 does not kill bacteria. Instead, it acts as an adsorbent within the intestinal lumen, sequestering harmful byproducts before they can cross the gut barrier. The beads are completely excreted after oral administration, ensuring no systemic absorption of the carbon itself.

Methodology

The study employed a comprehensive experimental workflow to validate the efficacy and safety of Yaq-001:

  1. In Vitro Characterization: Adsorption kinetics were measured for albumin, myoglobin, and endotoxins. Growth kinetics of E. coli and S. aureus were monitored to confirm the absence of antibiotic activity.
  2. In Vivo Rodent Models:
    • Cirrhosis Model: Rats underwent Bile Duct Ligation (BDL) for four weeks to simulate chronic liver injury.
  3. ACLF Model: BDL rats were given a "second hit" of LPS to trigger acute failure.
  4. Multi-Omics Analysis: To capture the systemic impact of a gut-restricted treatment, the team performed:
  5. Transcriptomics: Gene expression profiling in the liver, kidney, brain, and colon.
  6. Microbiome Sequencing: 16S rRNA analysis of fecal samples.
  7. Metabolomics: Urinary $^1$H-NMR signatures to track metabolic shifts.

Key Results

Improved Survival and Organ Function

In the ACLF model, Yaq-001 treatment significantly improved survival and delayed the time to coma. In the chronic BDL models, treated animals showed marked improvements in several clinical markers:

  • Liver Injury: Significant reduction in Alanine Aminotransferase (ALT) and liver cell death.
  • Hemodynamics: A notable decrease in portal pressure, which is the primary driver of variceal bleeding and ascites in cirrhosis.
  • Renal and Neurological Health: Treated rats exhibited lower plasma creatinine (improved kidney function) and reduced brain water (decreased edema).

Systemic Inflammation and the "Distant Organ" Effect

One of the study's most striking findings was that a treatment confined to the gut could modulate gene expression in distant organs. Transcriptome analysis revealed the downregulation of pro-inflammatory pathways (such as TLR signaling and cytokine-receptor interactions) in the liver, kidneys, and brain. This confirms that the "gut-liver axis" is part of a broader "gut-multi-organ axis" where intestinal health dictates systemic inflammatory tone.

Microbiome and Metabolomic Rebalancing

Rather than depleting the microbiome, Yaq-001 appeared to foster a more favorable microbial environment. Treatment was associated with a reduction in pro-inflammatory taxa, such as the Porphyromonadaceae family and Barnesiella genus. Furthermore, a reduction in D-lactate levels suggested improved intestinal barrier integrity, likely because the removal of luminal toxins allowed the gut lining to recover.

Discussion and Clinical Significance

The significance of this study lies in its demonstration of a non-antibiotic approach to managing bacterial translocation. By rapidly adsorbing endotoxins (60% adsorption within 30 minutes in vitro) and ammonia, Yaq-001 prevents the "priming" of immune cells like Kupffer cells in the liver. This reduction in immune sensitivity prevents the hyper-inflammatory response that typically leads to organ failure in ACLF.

While rodent models do not perfectly replicate the human microbiome, the consistency of the results across transcriptomic, metabolomic, and physiological data provides a robust foundation for human trials. Future research will need to ensure that long-term use of these beads does not inadvertently adsorb essential micronutrients, though no negative impact on animal weight or nutrition was observed in this study.

Conclusion

Yaq-001 represents a potential "first-in-class" therapy for cirrhosis. By acting as a selective adsorbent in the gut, it addresses the root cause of systemic inflammation without the risks associated with chronic antibiotic use. These preclinical data provide a strong rationale for proceeding to clinical trials aimed at preventing complications and improving survival in patients with chronic liver disease.

Summary updated

Abstract

Abstract Objective Translocation of gut bacterial lipopolysaccharide (LPS) is associated with complications of cirrhosis. Current strategies to target bacterial translocation are limited to antibiotics with risk of resistance. This study aims to explore therapeutic potential of a non-absorbable, engineered carbon bead, Yaq-001 in cirrhosis and acute-on-chronic liver failure (ACLF) models. Design The performance of Yaq-001 was evaluated in in vitro studies. Two-rodent models of cirrhosis (4-week, bile duct ligation (BDL): Sham (n=36); Sham-Yaq-001 (n=30); BDL (n=37); BDL-Yaq-001 (n=44)) and ACLF (BDL-LPS: Sham-LPS (n=9); Sham-LPS-Yaq-001 (n=10); BDL-LPS (n=16); BDL-LPS-Yaq-001(n=12)). The treated-groups received Yaq-001 for 2-weeks. Samples were collected for assessment of organ and immune function, transcriptomics, microbiome composition and metabolomics. Results In vitro , Yaq-001 exhibited rapid adsorption kinetics for endotoxin and bile acids without exerting an antibiotic effect. In vivo , Yaq-001 produced significant improvement in ALT, ammonia, liver cell death, portal pressure, markers of systemic inflammation and renal function in BDL animals. Yaq-001-treated ACLF animals had significantly better survival, ALT, portal pressure, brain water and creatinine. Ex-vivo LPS-induced reactive oxygen species production in portal venous monocytes and Kupffer cell populations was diminished with Yaq-001 treatment. Transcriptome analysis demonstrated a significant modulation of inflammation, cell death and senescence pathways in the liver, kidneys, brain and colon of Yaq-001-treated BDL rats. Yaq-001 impacted positively on the microbiome composition with significant modulation of Family Porphyromonadaceae and Genus Barnesiella . Urinary 1 HNMR analysis suggested a shift in metabolomic signature in Yaq-001-treated BDL rats. Conclusions This study provides strong pre-clinical rationale for developing Yaq-001 for treatment of patients with cirrhosis. Significance of this study What is already known on this topic? Current strategies to target bacterial translocation in cirrhosis are limited to antibiotics with risk of resistance. Yaq-001 is an insoluble, non-absorbable, non-antibiotic, engineered carbon bead of tailored porosities, which works as an adsorbent in the gut and is completely excreted after oral administration. What this study adds? Yaq-001 rapidly adsorbs endotoxin, ammonia and bile acids without influencing bacterial growth kinetics in vitro . Yaq-001 reduces mortality of ACLF animals and impacts positively on markers of gut permeability, liver injury, portal pressure, brain and kidneys in rodent models of cirrhosis and ACLF. Yaq-001 administration was associated with positive impact on the composition of the gut microbiota, reduction in severity of endotoxemia and ammonia, which significantly reduced the severity of inflammation, cell death, signaling pathways and LPS sensitivity. How this study might affect research, practice or policy? The data provide the pre-clinical rationale to proceed to clinical trials in patients with cirrhosis aiming to prevent the occurrence of complications.
BibTeX
@misc{liu2023impact,
  author = {Jinxia Liu and Jane Macnaughtan and Yi Jin and Frederick Clasen and Abeba Habtesion and Alexandra Phillips and Francesco De Chiara and Ganesh Ingavle and Paul Cordero-Sanchez and Junpei Soeda and Jude A. Oben and Jia Li and Haifeng Wu and Lindsey Edwards and I. Jane Cox and Susan Sandeman and Nathan Davies and Rajeshwar P. Mookerjee and Gautam Mehta and Saeed Shoaie and Julian R. Marchesi and Fausto Andreola and Rajiv Jalan},
  title = {{Impact of Yaq-001, a non-absorbable, engineered carbon bead of controlled porosity in rodent models of cirrhosis and acute on chronic liver failure}},
  year = {2023},
  doi = {10.1101/2023.08.15.553396},
  howpublished = {bioRxiv},
}
Figure